Zhonghui Bio-B (02627): Phase III clinical trial of freeze-dried human rabies vaccine (human diploid cells) begins

Zhitong Finance App News, Zhonghui Bio-B (02627) announced that the Group recently launched a phase III clinical trial of the Group's freeze-dried human rabies vaccine (human diploid cells). The company obtained a new drug clinical trial license approved by the State Drug Administration of the People's Republic of China for the Essen (five-dose) protocol in November 2022, and approved supplementary clinical trial applications for Zagreb (four doses) and the simple four-dose plan in April 2023. The company completed phase I clinical trials of the vaccine under development in October 2024.

Rabies is a serious viral disease caused by the rabies virus, which can cause severe symptoms such as confusion and progressive paralysis. Once symptoms develop, it's almost always fatal, but getting the right vaccine immediately after exposure to the virus can prevent rabies. The rabies vaccine developed using human diploid cells is the “gold standard” rabies vaccine recommended by WHO and has strong safety. The company's rabies vaccine under development has shown good safety characteristics in completed phase I clinical trials.